Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Nov 5, 2009


Calando Pharmaceuticals CEO James Hamilton has left the company, RNAi News has learned.

According to Calando CSO Thomas Schluep, Hamilton departed this summer. The CEO position has been filled by Christopher Anzalone, president and CEO of Calando’s parent firm Arrowhead Research.

Arrowhead also announced that Calando has named Mostafa Analoui and Bruce Given to its board of directors.

Analoui is currently head of healthcare and life science at the Livingston Group, a specialty investment firm, and senior vice president of business development at Charlesson Pharmaceuticals.

Given is currently the principal of Bruce Given Consulting, and previously served as president and CEO of Encysive Pharmaceuticals, which was acquired by Pfizer last year.

Rosetta Genomics said that it has named Kenneth Berlin as its new president and CEO.

Berlin replaces Amir Avniel, who announced in September that he would step down as Rosetta’s top official to become head of the company’s new plant biotechnology unit, Rosetta Green (see RNAi News, 9/10/2009).

Berlin previously served as worldwide general manager of Veridex, a Johnson & Johnson subsidiary focused on cellular and molecular cancer diagnostics. Before that, he was corporate counsel for Johnson & Johnson. He holds an AB from Princeton University and a JD from the University of California, Los Angeles, School of Law.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.